Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study

D’Amico, 2004, Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome, Semin Nephrol, 24, 179, 10.1016/j.semnephrol.2004.01.001 Wyatt, 2013, IgA nephropathy, N Engl J Med, 368, 2402, 10.1056/NEJMra1206793 Yeo, 2019, Is immunoglobulin A nephropathy different in different ethnic populations?, Nephrology (Carlton), 24, 885, 10.1111/nep.13592 Reich, 2007, Remission of proteinuria improves prognosis in IgA nephropathy, J Am Soc Nephrol, 18, 3177, 10.1681/ASN.2007050526 Thompson, 2019, Proteinuria reduction as a surrogate end point in trials of IgA nephropathy, Clin J Am Soc Nephrol, 14, 469, 10.2215/CJN.08600718 Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 1997, Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Zhao, 2019, Efficacy and safety of renin-angiotensin aldosterone system inhibitor in patients with IgA nephropathy: a meta-analysis of randomized controlled trial, Iran J Public Health, 48, 1577 Cheng, 2009, ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials, Int J Clin Pract, 63, 880, 10.1111/j.1742-1241.2009.02038.x Reid, 2011, Non-immunosuppressive treatment for IgA nephropathy, Cochrane Database Syst Rev, 3, CD003962 Cattran, 2009, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification, Kidney Int, 76, 534, 10.1038/ki.2009.243 Catapano, 2016, 2016 ESC/EAS Guidelines for the management of dyslipidaemias, Eur Heart J, 37, 2999, 10.1093/eurheartj/ehw272 2012, KDIGO clinical practice guideline for glomerulonephritis, Kidney Int Suppl, 2, 139 Praga, 2003, Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial, J Am Soc Nephrol, 14, 1578, 10.1097/01.ASN.0000068460.37369.DC Coppo, 2007, IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria, J Am Soc Nephrol, 18, 1880, 10.1681/ASN.2006040347 Li, 2006, HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study, Am J Kidney Dis, 47, 751, 10.1053/j.ajkd.2006.01.017 Shimizu, 2008, Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy, Hypertens Res, 31, 1711, 10.1291/hypres.31.1711 Li, 2013, Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor, Am J Med, 126, 162, 10.1016/j.amjmed.2012.06.028 Rauen, 2015, Intensive supportive care plus immunosuppression in IgA nephropathy, N Engl J Med, 373, 2225, 10.1056/NEJMoa1415463 Lv, 2017, Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial, JAMA, 318, 432, 10.1001/jama.2017.9362 Chacko, 2005, Presentation, prognosis and outcome of IgA nephropathy in Indian adults, Nephrology (Carlton), 10, 496, 10.1111/j.1440-1797.2005.00445.x Mittal, 2012, Primary IgA nephropathy in north India: is it different?, Postgrad Med J, 88, 15, 10.1136/postgradmedj-2011-130077 Bagchi, 2016, Clinical and histological profile of patients with primary IgA nephropathy seen in a tertiary hospital in India, Renal Fail, 38, 431, 10.3109/0886022X.2016.1138817